Vir Biotechnology Inc

VIR remains in a Stage 2 uptrend with price above all major EMAs, but the active Bullish Exhaustion pattern at fresh highs, tapering volume, and elevated Options Score signal buyer fatigue. Price is pulling back into the EMA ribbon amid cooling momentum, making timing unfavorable for new entries. We will defer buys (Stalk) until price resets into the 20-EMA zone or a decisive breakout above recent highs confirms renewed strength.

• ↑Q1 cash balance of $809.3M funds ops through 2H 2028.
• ↑Astellas collaboration worth up to $1.7B, with $75M upfront and $240M near term.
• ↓Q1 net loss $125.7M vs $121M LY and R&D spend $108.9M signals heavy cash burn.